Russian researchers develop a gut bacteria therapy to target multiple biological pathways in Parkinson's

Scientists in Russia are preparing a novel neurobiotic treatment that harnesses beneficial gut bacteria to tackle several underlying mechanisms of Parkinson's simultaneously. Announced at the OpenBio forum by Professor Valery Danilenko, scientific director of the Neurobiom consortium and head of biotechnology genetics at the Vavilov Institute of General Genetics, the experimental medicine is currently undergoing preclinical testing. If early laboratory evaluations continue smoothly, initial pilot trials involving humans are scheduled to begin between 2027 and 2028. Rather than concentrating solely on the brain, the development focuses heavily on the gut brain axis, which is the biochemical two way communication highway running between the digestive tract and the central nervous system. Over the years, medical research has highlighted how closely digestion, gut health, and neurological changes are linked. Building on this knowledge, researchers from the Vavilov Institute teamed up with the Russian Centre of Neurology and Neurosciences to screen different bacterial strains living in the human microbiome. Their search led them to a specific functional bacterium named Limosilactobacillus fermentum U21. The team chose this strain because it shows promise in addressing multiple biological challenges at once, rather than trying to fix just one isolated problem. In their investigations, the scientists monitored how this particular bacterium interacts with key markers of Parkinson's. They evaluated its ability to reduce oxidative stress, shield dopamine producing neurons from damage, and curb the troublesome clumping of alpha synuclein proteins. At the same time, they looked at how well the microbe protects the lining of the gut wall and whether those combined protective effects translate into improvements in physical movement. Professor Danilenko explained that because complex neurological conditions disrupt several biological systems at the same time, future therapies must be versatile enough to offer support across different organs. By treating the digestive environment as an active partner in brain health, the research team hopes this bacterium based approach could eventually serve as an effective supportive therapy alongside standard care.